March 2, 2020 / 8:36 AM / a month ago

BRIEF-Almirall: EMA Accepts Filing Of Marketing Authorization Application For Drug To Treat Actinic Keratosis

March 2 (Reuters) - Almirall SA:

* SAYS EMA ACCEPTANCE FOR FILING OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR TIRBANIBULIN IN ACTINIC KERATOSIS

* IT IS ESTIMATED THAT PEAK SALES OF TIRBANIBULIN WILL BE IN EXCESS OF 250 MILLION EUROS IN EUROPE AND IN THE US Source text: bit.ly/39fhDo1 Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below